Rick Chatwell, MD
Rheumatology · Lincoln, NENPI 1841260478
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 93 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by Amgen at 30.4% of the total. Reporting peaked in 2022 at $516 and has fallen 89.8% since, to $53 in 2025.
Across 93 payments — averaging $21.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$621
- GSK$219
- AbbVie$205
- Novartis$176
- Johnson & Johnson$174
- Pfizer$154
- plus $492 from 13 others
What the payments were for
- Food & beverage$2,02999%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 29 | $621 |
| GSK | 7 | $219 |
| AbbVie | 9 | $205 |
| Novartis | 5 | $176 |
| Johnson & Johnson | 10 | $174 |
| Pfizer | 4 | $154 |
| AstraZeneca(2 entities) | 6 | $111 |
| Aurinia Pharma U.S., Inc. | 4 | $82 |
| UCB, Inc. | 5 | $73 |
| Genentech USA, Inc. | 4 | $59 |
| Lilly USA, LLC | 2 | $36 |
| Mallinckrodt Hospital Products Inc. | 1 | $30 |
| Organon | 1 | $19 |
| Sandoz | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $14 |
| Janssen Scientific Affairs, LLC | 1 | $13 |
| Bristol Myers Squibb | 1 | $13 |
| Fidia Pharma USA Inc. | 1 | $10 |
How this compares
$2,041 in reported general payments places this provider in the 65th percentile of 39 rheumatology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 14 | $115,547 |
| MethotrexateMethotrexate Sodium | 167 | $3,449 |
| Hydroxychloroquine Sulfate | 66 | $2,579 |
| Prednisone | 253 | $1,185 |
| Sulfasalazine | 21 | $422 |
| Allopurinol | 30 | $371 |
| Alendronate Sodium | 39 | $297 |
| Leflunomide | 14 | $286 |
| Omeprazole | 24 | $236 |
| Diclofenac Sodium | 14 | $147 |
| Folic Acid | 18 | $58 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Lincoln
- Melvin ChurchillLincoln$14K
- Diana MeylerLincoln$12K
- Rasha AlqadiLincoln$1K
- Mashood BadshahLincoln$461
- Amy GarwoodLincoln$251
- Jennifer ElliottLincoln$221
- Robert ValenteLincoln$173
- Abhijeet DanveOmaha$118K
- Jay KenikOmaha$69K
- Lynell KlassenOmaha$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.